Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PIM 447

Drug Profile

PIM 447

Alternative Names: LGH-447; PIM447

Latest Information Update: 23 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Myelofibrosis

Most Recent Events

  • 17 Jul 2019 Phase-I development is still ongoing in Spain (NCT01456689)
  • 05 Jun 2019 Novartis completes a phase I trial in Multiple myeloma (Second-line therapy or greater) in USA, Germany, Singapore and Spain (NCT01456689)
  • 18 Apr 2019 Novartis completes a phase I trial in Myelodysplastic syndromes and Acute myeloid leukaemia (Monotherapy, Combination therapy, Second-line therapy or greater) in USA, Italy, Australia, France, Germany, Japan and Netherlands (PO) (NCT02078609)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top